Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Approach in Fight against Brain Cancer
Uncategorized

New Approach in Fight against Brain Cancer

By medwebDec 27, 2012
Share
Facebook Twitter Email
Alexander Stegh, assistant professor in the Ken and Ruth Davee Department of Neurology, is working to uncover the genetic underpinnings of Glioblastoma multiforme, the most common and deadly form of brain cancer. 

Enigmatic and incurable. 

These defining characteristics of the brain’s most common and aggressive form of cancer are what motivate the research of Alexander Stegh, PhD, assistant professor in the Ken and Ruth Davee Department of Neurology and medicine. 

Inside Stegh’s lab, researchers are working to uncover the genetic underpinnings of Glioblastoma multiforme (GBM), asking questions like: what are the genes critical for initiating the disease, and how is the disease driven? 

“We are also interested in learning why it is that most chemo-therapeutic drugs, including targeted GBM agents, fail in the clinic,” said Stegh, a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Brain Tumor Institute. “Some of these agents have certain efficacy in other forms of cancer with similar genetic backgrounds, but in GBM they are completely unsuccessful.” 

For the past year, Stegh has pursued this therapeutic paradox. Funded by the American Cancer Society Illinois Division, the project identified a novel oncogene that is overexpressed in GBM, and clarified the gene’s role in thwarting therapeutic response. 

“Moving forward, we have to continue to do a better job of understanding the genomic and genetic complexities of this disease,” Stegh said. “With The Cancer Genome Atlas – a program to identify the molecular basis of cancers – we took a huge step, but this appears only to be the tip of the iceberg. Right now, we only have an understanding of 10 percent of the genetic changes that are going on in GBM.” 

As scientists develop a more comprehensive understanding of those genetic changes, researchers will discover how they contribute to the disease. 

“Targeting these genes presents a very difficult challenge because many of them are unprecedented, meaning we have no idea how they work,” Stegh said. “Basically, we need a genetically-based technology such as RNA interference (RNAi) nanoparticles to actually target the genes we have already identified. That’s where I think bioengineering and nanotechnology come into play.” 

Working in collaboration with Chad Mirkin, PhD, director of the International Institute for Nanotechnology at Northwestern, Stegh used a Northwestern University Center of Cancer Nanotechnology Excellence grant to pursue an ambitious proof of concept project. 

The RNAi gold nanoparticles – measured in billionths of a meter – are able to turn off the production of an important cancer protein, acting as a potent inhibitor of tumor progression in vivo. 

“It is a completely novel approach in thinking about cancer therapy. One of the problems is that we have large lists of genes that are somehow disregulated in GBM cancers, but we have absolutely no way of targeting all of them using standard pharmacological approaches,” Stegh said. “That’s where we think nanomaterials, in particular RNAi-based nanomaterials, can play a fundamental role in allowing us to implement the concept of personalized medicine in cancer therapy.” 

Using the past 12 months to identify a target gene, Stegh’s lab will now work to pre-clinically evaluate an RNAi-based nanomaterial. The hope is to combine it with chemotherapy to increase the therapeutic sensitivity of GMB cancer cells and tumors.

Research
Share. Facebook Twitter Email

Related Posts

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Comments are closed.

Latest News

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.